News

Warfarin bridge therapy ups bleeding risk, with no reduction in VTE

View on the News

Bridging anticoagulation only for high-risk patients

Dr. Daniel J. Brotman

There are undoubtedly some patients at such high risk for recurrent venous thromboembolism that bridge therapy is a necessary evil, such as those with acute VTE in the preceding month and those with a prior pattern of brisk VTE recurrence during short-term interruption of anticoagulation therapy.

However, for the vast majority of patients receiving oral anticoagulants for VTE, it is probably safer to simply allow the oral anticoagulant to wash out before the procedure and, if indicated based on the type of surgery, to use routine prophylactic-dose anticoagulation therapy afterward.

Dr. Daniel J. Brotman and Dr. Michael B. Streiff are from Johns Hopkins University, Baltimore. These comments are taken from an accompanying editorial (JAMA Intern. Med. 2015 May 26 [doi:10.1001/jamainternmed.2015.1858]). Dr Streiff declared research funding from Bristol-Myers Squibb and Portola and consultancies for Boehringer-Ingelheim, Daiichi-Sankyo, Eisai, Janssen HealthCare, Pfizer, and Sanofi.


 

References

Bridge therapy for warfarin patients undergoing invasive therapy is unnecessary for most, said investigators who found an increased risk of bleeding associated with the use of short-acting anticoagulant at the time of the procedure.

A retrospective cohort study of 1,812 procedures in 1,178 patients – most of whom were considered to be at low risk of venous thromboembolism recurrence – showed a 17-fold increase in the risk of clinically relevant bleeding in the group that received bridge anticoagulant therapy, compared with the group that didn’t (2.7% vs. 0.2%).

Dr. Thomas Delate

Dr. Thomas Delate

There was, however, no significant difference in the rate of recurrent venous thromboembolism between the bridge-therapy and non–bridge-therapy groups (0 vs. 3), and no deaths were observed in either group, according to an article published online May 26 (JAMA Intern. Med. [doi:10.1001/jamainternmed.2015.1843].

“Our results confirm and strengthen the findings of those previous studies and highlight the need for a risk categorization scheme that identifies patients at highest risk for recurrent VTE who may benefit from bridge therapy,” wrote Thomas Delate, Ph.D., from Kaiser Permanente Colorado, and coauthors.

The study was conducted and supported by Kaiser Permanente Colorado. One author reported consultancies with Astra-Zeneca, Boehringer-Ingelheim, Pfizer, and Sanofi.

Recommended Reading

Upper airway stimulation an option in some patients
MDedge Surgery
Studies of anesthesia’s effect on upper airway are limited
MDedge Surgery
Avoid voriconazole in transplant patients at risk for skin cancer
MDedge Surgery
Biopsy bests HCRT for lung fibrosis, has risks
MDedge Surgery
Three-dimensional models show superiority of nanoparticles in mesothelioma
MDedge Surgery
ELCC: NSCLC mutation testing highlights ctDNA’s limitations
MDedge Surgery
ASA: Tumors glow green in new ‘optical biopsy’ technique
MDedge Surgery
Implantable filter doesn’t cut rate of recurrent PE
MDedge Surgery
ELCC: Urine tumor DNA shows high testing promise
MDedge Surgery
Asymptomatic carotid stenosis and central sleep apnea linked
MDedge Surgery